Updated: Alnylam scores OK for second-gen hATTR therapy as the space heats up
The latest rival to Alnylam’s drug for hereditary transthyretin-mediated (hATTR) amyloidosis is here — and it comes from Alnylam itself.
Four years after the groundbreaking approval of Onpattro, the world’s first RNAi therapy, the FDA has approved vutrisiran, Alnylam’s next-generation treatment for polyneuropathy of hATTR in adults. It will be marketed as Amvuttra.
Whereas Onpattro is administered as an intravenous injection every three weeks, Amvuttra is given subcutaneously once every three months.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.